



PRESS RELEASE

LAC Med Posts Higher FY2025 Profits, Expands Recurring Revenue Base with New Multi-Year Contract Wins

- LAC Med FY2025 net profit rises 7.5% to RM21.9 million on 10.0% higher revenue of RM201.6 million, driven by medical devices, increased recurring income
- RM216.7 million order book as at 15 February 2025; includes RM20.4 million new wins to deliver medical laboratory consumables and products


Selangor, Malaysia, 27 February 2026 - MedTech solutions provider, LAC Med Berhad (LAC Med or the Group; Bloomberg: LACMED MK) recorded a 7.5% increase in net profit to RM21.9 million in the financial year ended 31 December 2025 (FY2025), from RM20.4 million previously, underpinned by continued demand from private hospitals for medical devices and growing recurring income stream.

Fuelling the Group's earnings, revenue in FY2025 rose 10.0% to RM201.6 million, from RM183.2 million previously. The revenue increase was propelled by higher contribution from the Supply and Integration of Medical Devices segment, growing 48.6% to RM128.6 million from RM86.5 million previously.

Furthermore, revenue from the Supply of Related Products and Services segment increased 61.5% to RM24.5 million, from RM15.2 million previously. Segment growth was driven by higher sales of medical consumables and increased contributions from healthcare IT solutions, further boosting the Group's recurring income to sustain earnings.

Meanwhile, revenue from the Supply of Medical Equipment segment recorded RM48.5 million in FY2025, down 40.5% from a high base of RM81.5 million in the previous year. The decline was attributed to a significant order that the Group had secured from a public hospital and completed in the previous year.

During the financial year, the Group had expensed one-off listing expenses of RM2.6 million from its public listing exercise in 2025. Adjusting for this, the Group's core net profit would have been RM24.5 million in FY2025, a 20.1% increase compared with the previous year.





“We pride our capabilities in integration. With an expanded product range and services, we saw robust demand for our medical devices and solutions during the year, driven by expansion in the private healthcare sector in Malaysia. As healthcare demand continues to rise, LAC Med is ready to provide state-of-the-art medical technology solutions, supported by AI-powered assistance that accelerates diagnosis and decision-making in hospitals and clinics.

Looking ahead, we will continue to drive initiatives across our 11 brands to propel growth from multiple diagnostics areas, while spearheading digitalisation in Malaysia’s hospitals to build our recurring income streams. At the same time, LAC Med will focus on building operational efficiency and strengthening local partnerships to accelerate market penetration in Indonesia.”

Mr. Liew Yoon Poh (“刘任堡”)

Group Chief Executive Officer of LAC Med Berhad

LAC Med’s order book as at 15 February 2026 stood at RM216.7 million, including new wins worth RM20.4 million secured after its public listing in December 2025, to deliver medical laboratory consumables and products over a four-year period. Comparatively, the order book stood at RM184.6 million as at 15 October 2025, the latest practicable date of our IPO prospectus.

Mr. Liew added: “The recurring supply arrangements from the new wins will enhance our revenue visibility and position us for entry into previously unaddressed market segments. While the Group continues to expand the recurring and consumables-based revenue streams, we remain committed to maintaining margin discipline and operational efficiency across all segments.”

On the regional front, the Group officially commenced operations of PT Fairmed Nusajaya Imaging, a 95%-owned subsidiary company in July 2025, with all necessary licenses obtained from the relevant regulatory authorities in Indonesia. Entering the new financial year, its Indonesian subsidiary will be able to capture earnings fully, supported by an established existing base Alpinion products in the region.

In the fourth quarter ended 31 December 2025 (4Q25), group revenue stood at RM78.7 million with net profit of RM9.8 million. As this is the Group’s second interim financial report on consolidated results, there is no comparison to the preceding year corresponding quarter. LAC Med was listed on the Main Market of Bursa Malaysia Securities Berhad on 10 December 2025.



About LAC Med Berhad (LAC Med; the Group)

Established in 2004, LAC Med is a leading medical devices and integrated solutions provider. Through its subsidiaries, LAC Med has established itself as a trusted partner to service providers in the healthcare sector. LAC Med has installed an extensive base of more than 2,500 units of medical equipment and supports over 300 active clients across Malaysia’s healthcare sector, including private and public healthcare institutions, university hospitals, local health offices, medical device suppliers and concessionaire companies.

LAC Med’s competencies extend from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

As an authorised distributor in Malaysia and Indonesia, LAC Med supplies and installs third-party brands of medical devices comprising medical equipment and associated products, which include medical consumables and provision of software and system integration.

LAC Med represents leading international medical brands including Samsung and Philips, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also been appointed as an authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, annalise.ai, Alpinion, Baxter and Bayer, significantly strengthening its portfolio and its ability to deliver complete solutions for clients.

**Issued for and on behalf of LAC MED BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media and investor relations enquiries, please contact:**

Mr. Terence Loo	terence@aquilas.com.my	T:03-2711 1391/ M: 012-629 5618
Mr. Tee Wei Keat	weikeat@aquilas.com.my	T:03-2711 1391/ M: 012-309 5448